AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Breast cancer is one of the most common cancers in China - and it is on the rise
- Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes
- Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
- New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
- Pfizer announces extension of Zithromax® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness
Research & Development
- Probiotics can protect the skeletons of older women
- In mice, stem cells seem to work in fighting obesity! What about stem cells in humans?
- 'Kiss of death' cancer
- Research shows how a moderate dose of alcohol protects the heart
- Online information on vaccines and autism not always reliable, study shows
- Researchers find link between allergen in red meat and heart disease
- Big data identifies lipids as signatures of health and disease
Conferences & Events
- Ophthalmic Drugs Conference 2018
- SMi presents the launch of Cell & Gene Therapy 2018
- SMi presents the 9th Conference on Biosimilars & Biobetters
- SMi presents the 13th Conference on ADMET
- SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast
- Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018
- Adaptive Designs in Clinical Trials Conference 2018
Regulatory Affairs
- FDA takes steps to foster greater efficiency in biosimilar development by reconsidering draft guidance on evaluating analytical studies
- FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales
- FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment
- FDA takes new steps to advance digital health, opening docket to solicit feedback on software products
- FDA approves novel preventive treatment for migraine
- FDA approves first epoetin alfa biosimilar for the treatment of anemia
- FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients